Festival of Biologics USA
Festival of Biologics USA takes place on 13–14 April 2027 at Boston Convention & Exhibition Center (BCEC), Boston. It is organised by Terrapinn, and B2DB lists 107 speakers and 119 sessions announced so far.
Festival of Biologics USA is a two-day conference and exhibition in Boston covering antibodies, immunotherapy, clinical trials, discovery, development, manufacturing, fill and finish, and market access. It brings together pharma, biotech, physicians, payers and developers, with keynotes, panel discussions, interactive workshops and round tables, a poster zone and start-up pitches. For 2027 the event moves to Boston.
Key facts
| Dates | 13–14 April 2027 (upcoming) |
|---|---|
| Venue | Boston Convention & Exhibition Center (BCEC), Boston, United States of America |
| Organiser | Terrapinn |
| Series | Festival of Biologics USA |
| Speakers | 107 |
| Sessions | 119 |
| Stages | Keynotes, Biosimilars, AI & Data, Bioprocessing, Antibodies for Immunotherapy, Manufacturing, Protein Engineering, Clinical Trials, Finance & Investment, Innovation, mAbs, CMC, Advanced Therapies, Oncology, Armed Antibodies |
| Sponsors | 9 |
| Official site | terrapinn.com/conference/festival-of-biologics-usa/agenda.stm |
Keynote speakers
- Robert Dillman Chief Medical Officer, AIVITA Biomedical, Inc.
Speakers (107)
Compiled from the published agenda; speakers can claim and verify their own entry.
- Robert Dillman Chief Medical Officer, AIVITA Biomedical, Inc.
- Jae Sly CEO, Pathways Preclinical Partners
- Tatyana Matveeva Director of cGMP Operations, Mass General Hospital
- Maroun Beyrouthy, Ph.D. Senior Advisor, Eli Lilly and Company
- Mari Anne Snow CEO, Co-Founder, Eascra Biotech
- Sarajane Blair Director of Client Development & Partnerships, Cambridge Innovation Center
- Philip Beer Chief Scientific Officer, Step Pharma
- Adrian Hugenmatter Stanford University
- Alessandro Sette Professor, Co-Director, Center for Vaccine Innovation, La Jolla Institute for Allergy and Immunology
- Andrew DiChiara Senior Scientist II, Abbvie
- Andrew Tsourkas Professor of Bioengineering, University of Pennsylvania
- Anshika Gupta Project Scientist, UCI
- Anupam Chanda Principal Scientist, Bioxytran Inc, MA, Boston, USA
- Arlene Wolny Global Head of Regulatory Affairs, Kashiv Biosciences
- Ayla Sessions Associate Director, High-Throughput Production, AstraZeneca
- Brian Avanzino Director, Rondo Therapeutics
- Bruce Keyt CSO, Multivalent Biosciences
- Chaitanya Kankanala Sr. Engineer, Sanofi
- Chandrika Samir Patel Vice President - Global Regulatory Affairs, Kashiv BioSciences LLC.
- Changchun Du Senior Principal Scientific Researcher, Genentech
- Cheryl Marcotte Sr Director, GSK
- Chris Chumsae Director of Biophysical-Chemical Characterization, Bristol Myers Squibb
- Christina Hartman Head of Government Affairs and Washington, DC Office, Orchard therapeutics
- Christopher Kemball Senior Principal Scientist, Genentech
- Christopher Negron Research Scientist, AbbVie
- Christopher Wassif Senior Director-Emerging Technologies & High-Throughput Platforms, AstraZeneca
- Daniela Cipolletta Senior Director of Immunology, Seismic Therapeutic
- David Boggs Senior Scientist I - Protein Analytical Characterization Biotherapeutics and Genetic Medicine, Research and Discovery, Abbvie
- Dirk Zajonc VP, Protein Engineering, Mirador Therapeutics
- Elena Gonzalez Director of CMC, GenCART Bio
- Enrique Seoane-Vazquez Professor of Pharmaceutical Economics, Regulation and Policy, Chapman University
- Fariba Khanshan Director Radioconjugate PK/PD/PMX, AstraZeneca
- Genevieve Desjardins Associate Director in Protein Engineering, Zymeworks Inc
- Gordon Freeman Researcher, Dana Farber Cancer Institute
- Greg Hammond Head of Technical Operations, BioTalent
- Hanief Shahjee Associate Director, Teva Pharmaceuticals
- Hans Bitter Head of Computational Science & Data Strategy, Research, Takeda
- Hans van der Vliet Medical Oncologist, Amsterdam UMC
- Huub Gelderblom Director, Fred Hutch
- Ilya Tikh Sr. Principal Scientist, Pfizer
- J.P. Li ELITE Entrepreneurship Fellow, The Wharton School at the University of Pennsylvania
- Jakub Tomala Assistant Research Professor, John Hopkins University
- Jan Schnitzer Director, P.R.I.S.M.
- Jay Mandrekar Professor Of Biostatistics And Neurology, Mayo Clinic
- Jayasree Iyer Chief Executive Officer, Access to Medicine Foundation
- Jean-Francois Hamel Lecturer, Chemical Engineering, MIT
- Jennifer Chain CSM Industry Advocate, The Leukopak Lady
- Julio Baez Bioengineering Industrial Advisor, University of California San Diego
- Jun Zhang Associate Director, Amgen Inc
- Kamal Egodage Founder and President, Lasanth Consulting
- Kamal Joshi Principal Scientist, Bristol Myers Squibb
- Kamal Puri CSO, OncoResponse
- Kanika Sarpal Principal Scientist, Sanofi
- Keiichiro Kushiro Senior Director of Research, Mucommune
- Kenneth Galbraith Chair and CEO, Zymeworks
- Kenta Shinoda Principal Scientist, Pfizer
- Kim Walker Faculty Director & Graduate Advisor Center for Regulatory Science, San Diego State University
- Li Yi Executive Director, Formulation and Process Development, Gilead
- Lindsay Hammack Associate Principal Scientist, Merck
- Liviu Movileanu Professor, Department Of Physics, Syracuse University
- Marcello Marelli Director, AstraZeneca
- Marcie Black CEO, ASG
- Mark Mamula Professor Of Medicine Rheumatology, Yale University
- Marsha Crochiere Head of Translational Medicine and Research, PYXS Oncology
- Marvin Gee Chief Research Officer, 3T Biosciences
- Mats Sundgren Senior Industry Scientific Director, i-hd (The European Institute for Innovation through Health Data)
- Melody Chang VP of Pharmacy Operations, American oncology network
- Michael Peer Director of Computational Biology, Biolojic Design
- Nimi Vashi Co-Founder & CEO, Buzz Biolabs
- Olga Sharapova Senior Principal Scientist, Pfizer
- Parastoo Azadi Technical Director Of Analytical Services And Senior Research Scientist, Complex Carbohydrate Research Center
- Petra Duran Director of Patient Experience, ImYoo Health
- Philip Arlen President And Chief Executive Officer, Precision Biologics Inc
- Prasun Chakraborty Founder & CEO, Genevation LTD
- Qiang Chen Professor, Biodesign Institute at Arizona State University
- Rajarsi Gupta Assistant Professor, Stony Brook Medicine
- Rebecca Carlson Co-CEO, Deliverome Bio
- Riccardo Canevari CEO, Radiopharm Theranostics
- Richard Martel Operations Director, Bristol Myers Squibb
- Sanghoon Lee Associate Professor of Computer Science, Kennesaw State University
- Santosh Misal Scientist, National Institutes of Health
- Savita Bhutoria Senior Scientist, Gilead
- Shiva Bhowmik President + CSO, TRIO Pharmaceuticals, Inc.
- Sidharth Razdan Principal Scientist, Pfizer
- Sophia Humphreys VP, Health System Strategy & Innovation, MJH Life Sciences
- Sunny Zhou Professor, Northeastern University
- Takashi Ebihara GeneFrontier Corp.
- Vishwanath Hebbi Senior Scientist, Merck
- Yu Tian Director II, Abbvie
- Horacio Nastri VP protein science and technology, Incyte
- Jennifer Buchli LEO Program Chief Scientist, NASA
- Ken Savin Chief Scientific Officer, BioOrbit
- Nicole Wagner CEO, LambdaVision, Inc.
- Chris Bahl President of CSO, Co-founder, Ai Proteins
- Dunie Navarro Senior Scientist, Pfizer
- George Zhou Founder & CEO, Joint Biosciences
- Jian Yan Vice President, Research and Discovery, GENEOS THERAPEUTICS
- Kinkini Roy Director, Mohican Tx
- Maria Chiara Magnone Chief Scientific Officer, Abiologics
- Prasad Adusumilli Deputy Chief, Thoracic Surgery, Vice Chair, Department Of Surgery, Memorial Sloan-Kettering Cancer Center
- Roshan Ramanathan Founder and Executive Director, Bridges Initiative for Vaccine Regulatory Science and Practice
- Sabeen Mekan Chief Medical Officer, Zymeworks Inc
- Sarah Faruzzi Clinical Trials Lead, Retina Specialty Institute
- Shamekka Marty Patient Advocate, National Minority Health Association
- Vaibhav Deokar Principal Scientist, Lupin Limited
- William Paseman Founder, rarekidneycancer.org
- XingXing Zang Professor & Director, Albert Einstein College of Medicine
Most represented companies
- Pfizer — 5 speakers
- Abbvie — 4 speakers
- AstraZeneca — 4 speakers
- Bristol Myers Squibb — 3 speakers
- Genentech — 2 speakers
- Gilead — 2 speakers
- Merck — 2 speakers
- Sanofi — 2 speakers
- Zymeworks Inc — 2 speakers
Agenda (119 sessions)
Day 1 — Tuesday 13 April 2027
- Making high impact decisions across the value chain to effect access and affordability 09:10 · Keynotes — Jayasree Iyer
- Advances in Antibodies – the next generation of bispecifics and ADCs 09:30 · Keynotes — Kenneth Galbraith
- The Antibody Landscape: Latest Advances in Novel Multispecific Antibodies and ADCs 09:50 · Keynotes — Shiva Bhowmik
- Keynote Panel Discussion: AI in Biologics: Progress, Limits, and What Comes Next, sponsored by Cradle 10:10 · Keynotes — Robert Dillman
- New Development of Biosimilars in US, including Immunotherapy agents for cancer, such as pembrolizumab 11:00 · Biosimilars — Sophia Humphreys
- AI as Copilot, Not Autopilot: The Future of Decision-Making 11:00 · AI & Data — Jay Mandrekar
- Stable cell culture solutions: managing pH and temperature in bioreactors 11:00 · Bioprocessing — Jean-Francois Hamel
- Antibody discovery against GPCRs & antibodies as tools for small molecule discovery. 11:00 · Antibodies for Immunotherapy
- From start-up to scale: cGMP considerations and lessons from a cell therapy hub 11:00 · Manufacturing — Tatyana Matveeva
- Directed Evolution For Engineering Novel Proteins 11:00 · Protein Engineering — Adrian Hugenmatter
- Title TBA 11:20 · Manufacturing
- Title TBA 11:20 · Bioprocessing
- Title TBA 11:20 · Antibodies for Immunotherapy
- Predictive frameworks to improve drug discovery 11:40 · AI & Data — Yu Tian
- Formulation development for biologics 11:40 · Bioprocessing — Kanika Sarpal
- Launching a biosimilar: the US landscape for biosimilar products 11:40 · Biosimilars — Christina Hartman
- Building a Manufacturing Process in Low Earth Orbit — Infrastructure, Supply Chain and Regulatory Pathways 11:40 · Manufacturing — Mari Anne Snow
- Development of OR502, in antibody against leukocyte immunoglobulin-like receptor B2, to overcome suppression in the tumor microenvironment 11:40 · Antibodies for Immunotherapy — Kamal Puri
- Structural biology approaches to protein engineering 11:40 · Protein Engineering — Dirk Zajonc
- Cancer immunotherapy using bispecific gamma delta T cell engagers 12:00 · Antibodies for Immunotherapy — Hans van der Vliet
- Revolutionizing Cancer Care: the impact of biosimilars on the Community Oncology Frontline 12:00 · Biosimilars — Melody Chang
- Title TBA 12:00 · Protein Engineering — Kenta Shinoda
- Applying AI to the engineering novel antibody therapies 12:00 · AI & Data — Michael Peer
- Continuous downstream processing advances 12:00 · Bioprocessing — Vishwanath Hebbi
- The Patient Experience: Considering the Clinic and Beyond 12:45 · Clinical Trials — Petra Duran
- Title TBA 13:05 · Clinical Trials — Kim Walker
- Title TBA 13:25 · Clinical Trials — Cheryl Marcotte
- AI driven trial design and optimization 13:50 · AI & Data — J.P. Li
- Engineering protein scaffolds for novel bispecific antibodies 13:50 · Protein Engineering — Andrew Tsourkas
- Biophysical characterisation and analytics of novel proteins 13:50 · Manufacturing — David Boggs
- Bioprocessing to make biosimilars accessible 13:50 · Biosimilars — Julio Baez
- Maximizing the power of bispecific therapies for treating solid tumors 13:50 · Antibodies for Immunotherapy — Brian Avanzino
- Vector construction for protein expression 13:50 · Bioprocessing — Ilya Tikh
- Title TBA 14:10 · Manufacturing
- Title TBA 14:10 · Bioprocessing
- Title TBA 14:10 · Biosimilars
- Title TBA 14:10 · Protein Engineering
- Improved data generation for ML models using Continuous Directed Evolution Sequences 14:30 · AI & Data — Anshika Gupta
- Title TBA 14:30 · Manufacturing — Santosh Misal
- Real-Time and Label-Free Binding Kinetics of Membrane Protein-Ligand Interactions in a Membraneless and High-Throughput Setting 14:30 · Protein Engineering — Liviu Movileanu
- Title TBA 14:30 · Antibodies for Immunotherapy — Daniela Cipolletta
- Ensuring High Biosimilarity Through Advanced Processes and Characterization Approaches 14:30 · Biosimilars
- Polysaccharide drug substance production: Optimization and scale-up of purification unit operations 14:30 · Bioprocessing — Sidharth Razdan
- Cell‑Free Antibody Engineering: Accelerating Discovery and Screening with PUREfrex® 14:50 · AI & Data — Takashi Ebihara
- Title TBA 14:50 · Bioprocessing
- Exploring costimulatory receptors CD28 and 4-1BB for cancer immunotherapy 15:10 · Antibodies for Immunotherapy — Changchun Du
- Analytical development and characterization of biosimilars 15:10 · Biosimilars — Parastoo Azadi
- Automating Mid-scale Antibody Production: Bridging the Gap in Discovery Workflows with Novel Liquid Handling and Filtration Technologies 15:10 · Protein Engineering — Ayla Sessions
- Engineering challenges in manufacturing ADCs 15:10 · Manufacturing — Savita Bhutoria
- The Deliverome Project: Mapping Surface Protein Abundance and Internalization for Precision Delivery 15:10 · AI & Data — Rebecca Carlson
- Process characterization and purification of proteins 15:10 · Bioprocessing — Olga Sharapova
- Panel Discussion: Finance & Investment 15:30 · Finance & Investment — Jae Sly
- No one builds alone - How to create the best community, support systems, and teams 15:30 · Innovation — Sarajane Blair
- The Science of Talent in Biopharma – Measuring Human Performance as a Strategic Asset 15:50 · Innovation
- Engineering a novel mAb based contraceptive 16:40 · mAbs — Keiichiro Kushiro
- Engineered cytokine/antibody fusion proteins as novel drugs for cancer immunotherapy 16:40 · Protein Engineering — Jakub Tomala
- Streamlined Development: 2-year perspective what's changed 16:40 · Biosimilars — Arlene Wolny
- Examining novel cell expression platforms 16:40 · Bioprocessing — Nimi Vashi
- Leveraging AI in Computational Medicine 16:40 · AI & Data
- Title TBA 17:00 · Protein Engineering
- Title TBA 17:00 · Manufacturing
- Hybrid modality engineering 17:20 · Protein Engineering — Sunny Zhou
- Predicting the Regulators: How AI is Revolutionizing Biosimilar Development and Approval Strategy 17:20 · Biosimilars — Chandrika Samir Patel
- PANEL DISCUSSION: Scaling the Frontier: Key Logistics, Supply Chain, and Commercialisation Strategies in Cell Therapy Manufacturing 17:20 · Manufacturing
- A Roadmap for Actionable AI usage 17:20 · AI & Data
- The Immune Epitope and Cancer Epitopes Databases as Tools to Support Development and Testing of Biologics 17:20 · mAbs — Alessandro Sette
- The importance of talent: supporting the bioprocessing operations of tomorrow with the right people 17:20 · Bioprocessing — Greg Hammond
- An AI driven, cell-free vaccine platform 17:40 · AI & Data — Prasun Chakraborty
- Downstream operations for protein purification 17:40 · Protein Engineering — Richard Martel
- What the Biology Can't Fix: Good science doesn't automatically become good medicine. Some things have to be right before the biology even gets its chance 17:40 · Biosimilars
- Enhanced Antibody Effector Function Through Glycoengineering 17:40 · mAbs — Qiang Chen
Day 2 — Wednesday 14 April 2027
- Plenary Panel: Beyond the Atmosphere: Unlocking Space and Microgravity for Biologics Manufacturing and Commercialisation, sponsored by BioOrbit 09:45 · Keynotes — Mari Anne Snow, Jennifer Buchli, Ken Savin, Nicole Wagner
- Title TBA 11:00 · CMC
- Title TBA 11:00 · Protein Engineering
- Beginning with the End in Mind: Using the Target Product Profile to Guide Biologics Drug Product Development 11:20 · CMC — Li Yi
- Developing New Cancer Immunotherapies: From Bark to Bedside 11:20 · Advanced Therapies — Mark Mamula
- Trispecific antibody engineering: protein engineering fundamentals 11:20 · Protein Engineering — Genevieve Desjardins
- Advances in PD-1 Agonists 11:20 · Oncology — Gordon Freeman
- Advancing AI for Drug Discovery 11:20 · AI & Data — Hans Bitter
- PB-223, A Novel Antibody Drug Conjugate Targeting Truncated Core-2 Glycans in Solid Tumors 11:20 · Armed Antibodies — Philip Arlen
- Next Generation CAR-T for liquid tumours and autoimmune diseases 11:40 · Advanced Therapies — Elena Gonzalez
- Using AI ML to make Biobetters 11:40 · AI & Data — Christopher Negron
- A Novel CTPS1 Inhibition Approach 11:40 · Oncology — Philip Beer
- Approaches to developing cell based bioassays 11:40 · CMC — Hanief Shahjee
- From Hours to Minutes: Rapid Protein Measurement for Bioprocess Development and Manufacturing 11:40 · Protein Engineering — Marcie Black
- Novel ADCs, novel targets: engineering next generation therapies targeting non-cellular antigens 11:40 · Armed Antibodies — Marsha Crochiere
- Syntein™ Platform: AI-Designed D-Amino Acid Proteins as a New Class of Supranatural Protein Therapeutics 13:20 · AI & Data
- Next generation mAbs: new frontiers in cancer treatment 13:20 · Oncology — Huub Gelderblom
- Characterization of T Cell Engaging Bispecific Antibodies and Combination Therapies with a High-Throughput Multiparametric Automated Assay and Data Analysis Platform 13:20 · Protein Engineering — Christopher Kemball
- Analytical development of novel antibodies 13:20 · CMC — Chris Chumsae
- An autologous platform for production of novel Cell and Immunotherapies 13:20 · Advanced Therapies — Robert Dillman
- Advances in antibody-radioconjugate technology 13:20 · Armed Antibodies — Fariba Khanshan
- Radiopharmaceuticals for oncology 14:00 · Armed Antibodies — Riccardo Canevari
- Developing T cell Engagers Against novel pHLA Targets 14:00 · Oncology — Marvin Gee
- Stability support for early clinical programs 14:00 · CMC — Jun Zhang
- From Discovery to Market: U.S. Leadership in Gene Therapy Innovation 14:00 · Advanced Therapies — Enrique Seoane-Vazquez
- Integration of Survival Analysis and Workflow Assistant on a Hybrid Interactive Machine Learning Tool for Whole Slide Image Analysis 14:00 · AI & Data — Sanghoon Lee
- Protein generation to support exploratory immunology 14:00 · Protein Engineering — Andrew DiChiara
- Title TBA 14:20 · Advanced Therapies — Jennifer Chain
- Novel ligan-based bispecific drug conjugates targeting prostate cancer 14:20 · Oncology — Bruce Keyt
- Applications of AI/ML in Packaging Development for Biosimilar Products 14:20 · AI & Data — Anupam Chanda
- Precision Bioconjugation to Build Next-Generation Biotherapeutics 14:20 · Armed Antibodies
- Advances in high throughput screening technologies for antibody production 14:20 · Protein Engineering — Christopher Wassif
- Selecting biologic candidates to accelerate development and reduce costs 14:20 · CMC — Kamal Egodage
- Unnatural Precision: Site-specific conjugation for next generation ADCs 14:40 · Armed Antibodies — Marcello Marelli
- De novo designs for recombinant antibodies 14:40 · Protein Engineering — Lindsay Hammack
- Advancing novel cancer treating antibody therapies, powered by AI 14:40 · Oncology — Jan Schnitzer
- From Propagation to Push-Button: Ready-to-Use Cells and Robotic Liquid Handling in Bioassay QC Lab 14:40 · CMC — Maroun Beyrouthy, Ph.D.
- Managing Clinical Data Effectively and Securely 14:40 · AI & Data — Mats Sundgren
- Engineering Next-Generation T-Cell Engagers for Solid Tumors 15:00 · Protein Engineering — Kamal Joshi
- Pathomics tools to Map and Quantify TILs in Cancer for Precision Oncology 15:00 · AI & Data — Rajarsi Gupta
- Accelerating mRNA Purification Process Development Through Mechanistic Modeling of Oligo-dT Chromatography 15:00 · CMC — Chaitanya Kankanala
- Engineering Antibody–Bottlebrush Conjugates for Targeted Cancer Therapy 15:00 · Armed Antibodies
- Panel Discussion: Beyond the Hype: AI's Real Impact on Biologics Development 15:40 · AI & Data
- Panel Discussion: The Protein Engineer's Toolkit: Trends Shaping Next-Generation Biologics 15:40 · Protein Engineering — Horacio Nastri
- Panel Discussion: Payload Precision: Next-Generation ADCs and Beyond 15:40 · Armed Antibodies
- Panel Discussion: The Next Wave of Oncology Biologics: Combination Strategies and Resistance 15:40 · Oncology
- Panel Discussion: Scaling Smart: De-Risking Biologics CMC and Supply Chains 15:40 · CMC
- Panel Discussion: From Bench to Bedside: Overcoming CGT Commercialization Hurdles 15:40 · Advanced Therapies — Sarajane Blair
Organisers, sponsors and partners
Organiser (1)
Sponsors (9)
Varda Space Industries · SCIEX · BioOrbit · Fluidic Sciences Ltd · FUJIFILM Biotechnologies · KBI Biopharma · ECOLAB · GeneFrontier Corp. · Bio X Cell
Exhibitors (14)
GeneUniversal · SCIEX · Ajinomoto Co., Inc. · Grand River Aseptic Manufacturing · Malvern Panalytical GmbH · ProteoGenix · Vector Laboratories · KBI Biopharma · Gerresheimer · Genizer LLC · Nuclera · Nitto Avecia Pharma Services · MedChemExpress · BPS BIOSCIENCE INC
Startups (2)
Avenue Biosciences · CamBioLogics
Source: the published agenda. See how B2DB compiles its records.